Cynthia X. Ma, MD, PhD, on Breast Cancer: Neoadjuvant Endocrine Treatment for ER-Positive, HER2-Negative Disease
ASCO20 Virtual Scientific ProgramCynthia X. Ma, MD, PhD, of Washington University, discusses results from the ALTERNATE trial, which showed neither fulvestrant nor fulvestrant plus anastrozole significantly improved endocrine-sensitive disease rate compared with anastrozole alone in postmenopausal patients with locally advanced estrogen receptor–positive, HER2-negative breast cancer (Abstract 504).
Related Videos
Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve...
Welcome to This Year’s Meeting: A Message From ASCO President Howard A. Burris III, MD, FACP, FASCO
Howard A. Burris III, MD, FACP, FASCO, President of ASCO, talks about what to expect from this year’s ASCO20 Virtual Scientific Program and its many offerings.
Daniel P. Petrylak, MD, on Prostate Cancer: First-in-Human Study of ARV-110 Shows Antitumor Activity
Daniel P. Petrylak, MD, of the Yale Cancer Center, discusses early data on ARV-110, an androgen receptor proteolysis–targeting chimera degrader, demonstrating antitumor activ...
Eric Jonasch, MD, on a Novel Therapy for Von Hippel-Lindau Disease–Associated RCC
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study findings on the oral HIF-2α inhibitor known as MK-6482, which showed efficacy...
Richard L. Schilsky, MD, on This Year’s Practice-Changing Findings
Richard L. Schilsky, MD, Chief Medical Officer of ASCO, talks about some of the most important and practice-changing findings presented this year at...
